On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc and GitLab Inc. These trades reflect Ark’s strategic positioning in the tech and AI sectors, following recent earnings reports from both companies.
Ark Invest’s ARK Innovation ETF acquired 225,833 shares of Tempus AI, while ARK Genomic Revolution ETF purchased 44,969 shares. The transactions were valued at $13.23 million. For the day, Tempus AI shares ended 7.9% lower at $48.86.
These trades come after Tempus AI’s recent quarterly earnings report, which showed a revenue miss but an earnings-per-share beat. The company reported fourth-quarter revenue of $200.68 million, falling short of the $203.12 million estimate. However, its adjusted loss of 18 cents per share was better than the anticipated 20-cent loss.
Despite the mixed results, Tempus AI provided strong guidance. Analysts have varied opinions on Tempus AI, with some expressing bullish sentiments while others remaining cautious.
On the same day, Ark Invest’s ARKK and ARK Next Generation Internet ETF collectively purchased 86,906 shares of GitLab. This trade was valued at $5.06 million based on Thursday’s closing price of $58.25.
This move follows GitLab’s impressive fourth-quarter earnings report, which exceeded expectations. GitLab reported earnings of 33 cents per share, surpassing the consensus estimate of 23 cents. Additionally, its revenue of $211.43 million beat the expected $206.12 million.
Purchased Ibotta Inc. (IBTA) stock through ARKK and ARKF
Purchased Recursion Pharmaceuticals Inc. (RXRX) shares through ARKG.
Sold shares of Uipath Inc. (PATH) via ARKK and Draftkings Inc. (DKNG) through ARKW.
ARKG sold Repare Therapeutics Inc. (RPTX) and Exact Sciences Corp. (EXAS) stock
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。